BUSINESS PROFILE :
Glenmark Pharmaceuticals (GPL) is engaged in research and development, manufacturing and marketing of branded formulations in India and abroad. Its business segments include India API, exports formulations and API NCE research. It markets products in 70 countries including the regulated markets of the Europe and USA. It has been involved in new drug discoveries such as new molecules for asthma, obesity and diabetes segments. Glenmark has been involved in API business. Glenmark conducts its operations through its manufacturing plants including Baddi, Goa, Nasik and Sao Paulo, Brazil for formulations and Ankleshwar, Kurkumbh and Solapur for API.
Its research activities encompass process engineering for APIs, new chemical entity research and novel drug delivery systems [NDDS]. The company also operates a second research facility at Sinnar, India that focuses on developing formulations for India and markets across Asia, Africa, Latin America and CIS/Russia. The company is further researching PDE-4 inhibitors for CNS indications, cognitive disorders and inflammatory conditions such as atopic dermatitis, ulcerative colitis and rheumatoid arthritis. Other research areas include diabetes segment in which the company has a DPP-IV target, GRC 8200, in Phase I clinical trials.
The company as part of its R&D is working on new molecules in various segments namely antihypertensive molecules, antifungal molecules, antibacterial molecules, technology such as microspheres and aerosols, development of formulations for semi regulatory markets. It is also targeting development and technology transfer and ANDA filing for 10-12 products.
|
